Summary
AbbVie’s Emrelis, an FDA-approved drug, targets c-Met proteins in NSCLC for effective cancer treatment, marking significant advancements in antibody-drug conjugates (ADCs).
The article discusses the FDA’s accelerated approval of AbbVie’s new drug, Emrelis. Emrelis treats a specific type of advanced non-small cell lung cancer (NSCLC) that expresses high levels of the c-Met protein.
Around one-quarter of advanced NSCLC patients overexpress the c-Met protein, and Emrelis targets this protein to attack cancer cells. Emrelis is an example of an antibody-drug conjugate (ADC). ADCs are clones of antibodies designed to bind to proteins found in cancer cells, and each antibody is attached to a cancer cell-destroying drug.
AbbVie is also running additional studies to confirm Emrelis’s benefits and evaluate its performance against chemotherapy. The company aims to refine patient selection who would benefit the most from this drug, particularly using it as a second or third option in treatment.
Many oncologists view Emrelis as a beneficial advancement in cancer treatment, especially noting its innovative application in treating tumors. Experts see ADCs as increasingly crucial in managing solid tumors beyond their previous use in blood cancers. This progress reflects AbbVie’s strong commitment to this innovative treatment approach and its potential to significantly impact cancer care.
